Primary Care/Hospitalist
RSSArticles
-
With unsurpassed efficacy and rapid reversibility, contraceptive implant can be put into practice
While use of long-acting reversible contraceptive (LARC) methods is growing, the contraceptive implant (Nexplanon, Merck & Co., Whitehouse Station, NJ) is still underused, say family planning experts. Look at the most recent national figures: In 2009, 8.5% of women using contraceptives relied on LARC methods, rising from 5.5% in 2007 and 2.4% in 2002. However, most of these women (nearly 8%) use intrauterine devices (IUDs), compared to less than 1% who use the implant.
-
Ortho Evra patch discontinued — What next?
Rewind to 2002: The first transdermal contraceptive, the Ortho Evra patch, hit U.S. pharmacy shelves. Fast forward to the present: The manufacturer has production of the device “due to a business decision,” according to information on the Food and Drug Administration (FDA) website.
-
CTU remembers Michael Rosenberg, MD, MPH
The reproductive health research community is paying tribute to Michael Rosenberg, MD, MPH, founder and chief executive officer of the Durham, NC-based clinical research organization, Health Decisions. Rosenberg was killed in a Dec. 8 plane crash in Maryland.
-
For Methods that are Reversible and Long-acting, the Upswing Continues
Our annual contraception survey shows “dramatically more” women choosing intrauterine and implant contraception.
-
Empagliflozin Tablets (Jardiance ®)
A new sodium glucose co-transporter 2 (SGLT2) has been approved by the FDA. Empagliflozin follows canagliflozin (Invokana) and dapagliflozin (Farxiga)as the third entry in this group. These drugs reduce plasma glucose levels by reducing renal absorption of filtered glucose. Empagliflozin is marketed by Boehringer Ingelheim as Jardiance. -
Good Ol’ Vitamin C: Does It Deserve Another Look for Your Heart?
SYNOPSIS: A meta-analysis and systematic review found vitamin C supplementation improved endothelial function in patients with diabetes, atherosclerosis, and heart failure. -
Stopping Colonoscopy at Age 75 ¡ª Even With a History of Colon Cancer
SYNOPSIS: The incidence of colorectal cancer is much less in people > 75 years of age compared with ages 50-74, even in patients with a personal history of colon cancer or adenomatous polyps. Complication rates for colonoscopy are high in the elderly ¡Ý age 75 and in patients with comorbidities. Surveillance colonoscopy may be stopped in the advanced elderly and in comorbid elderly patients. -
Bring on the Butter and the Eggs
SYNOPSIS: People who were randomized to a low-carbohydrate diet lost more weight than those who were randomized to a low-fat diet over a year. They also had greater improvements in risk factors for cardiovascular disease. -
CLINICAL BRIEFS
The highest morbidity and mortality consequences of influenza occur in senior citizens. The efficacy of standard flu vaccine varies depending on the outcome that is examined -
OnabotulinumtoxinA for Treatment of Chronic Migraines
A pooled analysis of four clinical trials concluded that treatment with onabotulinumtoxinA at doses of 75-260 U administered every 12 weeks for up to five treatment cycles was efficacious, safe, and well tolerated for the prophylaxis of headache in adults with chronic migraine.